Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H41NO4 |
Molecular Weight | 491.6615 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC(C)(C)CC[C@@]1(CC[C@]3(C)[C@]2([H])C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O
InChI
InChIKey=TXGZJQLMVSIZEI-UQMAOPSPSA-N
InChI=1S/C31H41NO4/c1-26(2)10-12-31(25(35)36)13-11-30(7)23(19(31)16-26)20(33)14-22-28(5)15-18(17-32)24(34)27(3,4)21(28)8-9-29(22,30)6/h14-15,19,21,23H,8-13,16H2,1-7H3,(H,35,36)/t19-,21-,23-,28-,29+,30+,31-/m0/s1
Molecular Formula | C31H41NO4 |
Molecular Weight | 491.6615 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
2-Cyano-3,12-dioxooleana-1,9-diene-28-oic acid (CDDO, also known as Bardoxolone) is a synthetic triterpenoid that displays potent anti-inflammatory and antitumorigenic activities. CDDO was in the clinical trial phase I for the treatment patients with Solid tumors and leukemia, but that studies were discontinued. It is known, that CDDO blocks the cellular synthesis of inducible nitric oxide synthase and inducible COX-2. In addition, was discovered, that CDDO disrupted intracellular redox balance and thereby induce apoptosis. Moreover, CDDO is a ligand for peroxisome proliferator-activated receptor that it induces genes regulated by Nrf2, including heme oxygenase-1 and eotaxin-1, which play a role in antioxidant response element signaling activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35228|||Q9UD42 Gene ID: 4843.0 Gene Symbol: NOS2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9873608 |
|||
Target ID: intracellular redox balance Sources: https://www.ncbi.nlm.nih.gov/pubmed/14500394 |
|||
Target ID: P37231|||Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/14522919 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22634319 |
900 mg 1 times / day steady-state, oral dose: 900 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BARDOXOLONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
28.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22634319 |
1300 mg 1 times / day steady-state, oral dose: 1300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BARDOXOLONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20370 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22634319 |
900 mg 1 times / day steady-state, oral dose: 900 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BARDOXOLONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
24411 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22634319 |
1300 mg 1 times / day steady-state, oral dose: 1300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BARDOXOLONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22634319 |
900 mg 1 times / day steady-state, oral dose: 900 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BARDOXOLONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
34 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22634319 |
1300 mg 1 times / day steady-state, oral dose: 1300 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BARDOXOLONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1300 mg 1 times / day multiple, oral Highest studied dose Dose: 1300 mg, 1 times / day Route: oral Route: multiple Dose: 1300 mg, 1 times / day Sources: Page: p.7 |
unhealthy, ADULT n = 9 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 9 Sources: Page: p.7 |
DLT: ALT increased... Dose limiting toxicities: ALT increased (grade 3, 22.2%) Sources: Page: p.7 |
900 mg 1 times / day multiple, oral MTD Dose: 900 mg, 1 times / day Route: oral Route: multiple Dose: 900 mg, 1 times / day Sources: Page: p.7 |
unhealthy, ADULT n = 25 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 25 Sources: Page: p.7 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ALT increased | grade 3, 22.2% DLT, Disc. AE |
1300 mg 1 times / day multiple, oral Highest studied dose Dose: 1300 mg, 1 times / day Route: oral Route: multiple Dose: 1300 mg, 1 times / day Sources: Page: p.7 |
unhealthy, ADULT n = 9 Health Status: unhealthy Condition: cancer Age Group: ADULT Sex: M+F Food Status: FASTED Population Size: 9 Sources: Page: p.7 |
Sample Use Guides
infusion for 5 consecutive days in 28-day cycle
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9927043
CDDO induced monocytic differentiation of human myeloid leukemia cells and adipogenic differentiation of mouse 3T3-L1 fibroblasts and enhanced the neuronal differentiation of rat PC12 pheochromocytoma cells caused by nerve growth factor. CDDO inhibited proliferation of many human tumor cell lines, including those derived from estrogen receptor-positive and -negative breast carcinomas, myeloid leukemias, and several carcinomas bearing a Smad4 mutation. Furthermore, it suppressed the abilities of various inflammatory cytokines, such as IFN-gamma, interleukin-1, and tumor necrosis factor-alpha, to induce de novo formation of the enzymes inducible nitric oxide synthase (iNos) and inducible cyclooxygenase (COX-2) in mouse peritoneal macrophages, rat brain microglia, and human colon fibroblasts. The above activities had been found at concentrations ranging from 10(-6) to 10(-9) M in cell culture.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:05:04 GMT 2023
by
admin
on
Fri Dec 15 16:05:04 GMT 2023
|
Record UNII |
7HT68L8941
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1323
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
||
|
NCI_THESAURUS |
C29574
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
456114
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
||
|
FDA ORPHAN DRUG |
264108
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7HT68L8941
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
UU-156
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
DB12651
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
DTXSID001025273
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
711193
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
300000000141
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
C48382
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
9108
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
218600-44-3
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL1093059
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | |||
|
m2229
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
400010
Created by
admin on Fri Dec 15 16:05:04 GMT 2023 , Edited by admin on Fri Dec 15 16:05:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> ACTIVATOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|